{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:53:32Z","timestamp":1781636012511,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Palbociclib (PAL), a cyclin-dependent kinase 4\/6 inhibitor, plus endocrine therapy (ET) is recommended as first-line (1L) treatment for hormone receptor-positive (HR+)\/ human epidermal growth factor 2 negative (HER2-) advanced breast cancer (ABC). Despite broad use in real-world clinical settings, few studies have evaluated its effectiveness in elderly patients in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The multicenter, observational P-BRIDGE study included HR+\/HER2- ABC patients (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009693) who initiated PAL\u2009+\u2009ET as 1L or second-line treatment during 2017\u20132020 in Japan. Treatment outcomes and patterns were evaluated by age category (&lt;\u200965; \u2265 65 to &lt;\u200975; \u2265 75 years).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among patients treated with 1L PAL\u2009+\u2009ET (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009426), 266, 118, and 42 patients were aged\u2009&lt;\u200965, \u2265 65 to &lt;\u200975, and \u2265\u200975 years, respectively. Patients aged\u2009\u2265\u200975 years were less likely to initiate PAL at 125\u00a0mg (64.3%) than patients aged\u2009&lt;\u200965 (95.5%) and \u2265\u200965 to &lt;\u200975 (88.1%) years. More patients aged\u2009\u2265\u200975 years discontinued PAL due to adverse events than other age groups. Median real-world progression-free survival (95% CI) was 24.5 months (18.2\u201330,4), 25.7 months (16.8\u201336.7), and 45.4 months (20.4\u201352.4), in the &lt;\u200965, \u2265 65 to &lt;\u200975, and \u2265\u200975-year age groups, respectively. Corresponding median overall survival was 68.2 months (65.0-not reached [NR]), NR (56.3-NR), and 68.0 months (45.8-NR), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The effectiveness of PAL\u2009+\u2009ET in elderly patients in the real-world setting in Japan appears comparable to other age groups. These findings support PAL\u2009+\u2009ET as a viable treatment option for all patients, including the elderly, while highlighting the need for close monitoring and individualized treatment strategies, especially in older patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12282-025-01812-5","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:12:28Z","timestamp":1770790348000},"page":"333-345","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+\/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group"],"prefix":"10.1007","volume":"33","author":[{"given":"Hiroko","family":"Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2887-6066","authenticated-orcid":false,"given":"Shigenori E.","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuho","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Tsuneizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takabatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Harao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yasojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiya","family":"Oshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madoka","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Sangai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Sasada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Futamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-0278","authenticated-orcid":false,"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"1812_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.critrevonc.2017.02.022","volume":"112","author":"SP Corona","year":"2017","unstructured":"Corona SP, Ravelli A, Cretella D, Cappelletti MR, Zanotti L, Dester M, et al. CDK4\/6 inhibitors in HER2-positive breast cancer. Crit Rev Oncol Hematol. 2017;112:208\u201314.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"1812_CR2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s12282-020-01085-0","volume":"27","author":"T Shimoi","year":"2020","unstructured":"Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, et al. The Japanese breast cancer society clinical practice guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27(3):322\u201331.","journal-title":"Breast Cancer"},{"issue":"12","key":"1812_CR3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395.","journal-title":"Ann Oncol"},{"issue":"3","key":"1812_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Finn RS, Di\u00e9ras V, Ettl J, Lipatov O, Joy AA, et al. Palbociclib plus letrozole as first-line therapy in Estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174(3):719\u201329.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1812_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus Palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425\u201339.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1812_CR6","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.00137","volume":"42","author":"DJ Slamon","year":"2024","unstructured":"Slamon DJ, Di\u00e9ras V, Rugo HS, Harbeck N, Im S-A, Gelmon KA, et al. Overall survival with Palbociclib plus letrozole in advanced breast cancer. J Clin Oncol. 2024;42(9):994\u20131000.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1812_CR7","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S-A, Masuda N, et al. Overall survival with Palbociclib and fulvestrant in advanced breast cancer. New Engl J Med. 2018;379(20):1926\u201336.","journal-title":"New Engl J Med"},{"issue":"12","key":"1812_CR8","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1001\/jamaoncol.2019.2055","volume":"5","author":"EB Ludmir","year":"2019","unstructured":"Ludmir EB, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5(12):1769\u201373.","journal-title":"JAMA Oncol"},{"issue":"Suppl 1Suppl 1","key":"1812_CR9","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.2105\/AJPH.2009.162982","volume":"100","author":"AP Herrera","year":"2010","unstructured":"Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010;100(Suppl 1Suppl 1):S105\u201312.","journal-title":"Am J Public Health"},{"issue":"1","key":"1812_CR10","first-page":"78","volume":"71","author":"MS Sedrak","year":"2021","unstructured":"Sedrak MS, Freedman RA, Cohen HJ, Muss HB, Jatoi A, Klepin HD, et al. Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. CA Cancer J Clin. 2021;71(1):78\u201392.","journal-title":"CA Cancer J Clin"},{"key":"1812_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejca.2018.05.017","volume":"101","author":"HS Rugo","year":"2018","unstructured":"Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, et al. Palbociclib plus endocrine therapy in older women with HR+\/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018;101:123\u201333.","journal-title":"Eur J Cancer"},{"key":"1812_CR12","doi-asserted-by":"publisher","first-page":"1237751","DOI":"10.3389\/fonc.2023.1237751","volume":"13","author":"A Brufsky","year":"2023","unstructured":"Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, et al. Real-world treatment patterns and effectiveness of Palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Front Oncol. 2023;13:1237751.","journal-title":"Front Oncol"},{"issue":"16suppl","key":"1812_CR13","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1200\/JCO.2023.41.16_suppl.1018","volume":"41","author":"E Carola","year":"2023","unstructured":"Carola E, Pulido M, Falandry C, Paillaud E, Caillet P, Tassy L, et al. First-line systemic treatment with Palbociclib in women aged\u2009\u2265\u200970 years presenting with hormone receptor-positive advanced breast cancer: results from the PALOMAGE program. J Clin Oncol. 2023;41(16suppl):1018\u201318.","journal-title":"J Clin Oncol"},{"key":"1812_CR14","doi-asserted-by":"crossref","unstructured":"Nagai SE, Hattori M, Yoshinami T, Masuda H, Okamura T, Watanabe K et al. Overall survival of Palbociclib plus endocrine therapy in Japanese patients with HR+\/HER2\u2013 advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study). Breast Cancer. 2025.","DOI":"10.1007\/s12282-025-01689-4"},{"issue":"14","key":"1812_CR15","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1002\/cam4.3091","volume":"9","author":"M Takahashi","year":"2020","unstructured":"Takahashi M, Masuda N, Nishimura R, Inoue K, Ohno S, Iwata H, et al. Palbociclib-letrozole as first-line treatment for advanced breast cancer: updated results from a Japanese phase 2 study. Cancer Med. 2020;9(14):4929\u201340.","journal-title":"Cancer Med"},{"issue":"2","key":"1812_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10549-024-07312-y","volume":"206","author":"JC Baltussen","year":"2024","unstructured":"Baltussen JC, Mooijaart SP, Vulink AJE, Houtsma D, Van der Deure WM, Westerman EM, et al. Tolerability and effectiveness of Palbociclib in older women with metastatic breast cancer. Breast Cancer Res Treat. 2024;206(2):337\u201346.","journal-title":"Breast Cancer Res Treat"},{"issue":"15suppl","key":"1812_CR17","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1200\/JCO.2021.39.15_suppl.1012","volume":"39","author":"P Caillet","year":"2021","unstructured":"Caillet P, Pulido M, Brain E, Falandry C, Desmoulins I, Ghebriou D, et al. PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: baseline characteristics and safety evaluation. J Clin Oncol. 2021;39(15suppl):1012\u201312.","journal-title":"J Clin Oncol"},{"key":"1812_CR18","doi-asserted-by":"publisher","first-page":"Jgo1800239","DOI":"10.1200\/JGO.18.00239","volume":"5","author":"J Waller","year":"2019","unstructured":"Waller J, Mitra D, Mycock K, Taylor-Stokes G, Milligan G, Zhan L, et al. Real-world treatment patterns and clinical outcomes in patients receiving Palbociclib for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in argentina: the IRIS study. J Glob Oncol. 2019;5:Jgo1800239.","journal-title":"J Glob Oncol"},{"key":"1812_CR19","doi-asserted-by":"crossref","unstructured":"Brain E, Pulido M, Paillaud E, Grosjean J, Mina W, Caillet P et al. Abstract P1-18-04: Feasibility of palbociclib in women aged 70 and older with resistant and\/or pretreated advanced breast cancer in the PALOMAGE study. Cancer Res. 2022;82(4_Supplement):P1-18-04-P1-18-04.","DOI":"10.1158\/1538-7445.SABCS21-P1-18-04"},{"key":"1812_CR20","unstructured":"Carola E, Pulido MC, Falandry C, Tassy L, et al. Palbociclib in women aged\u2009\u2265\u200970 years as first-line treatment for endocrine-sensitive hormone receptor-positive\/human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: final results of PalomAGE. San Antonio Breast Cancer Symposium. 2024. https:\/\/www.pfizermedicalpfizerprocom\/api\/vc\/en\/medical\/assets\/b9ead6c5-2925-4d95-95d0-126448779bec\/Carola_P_P2-07-17_SABCS2024.pdf. Accessed 4 Apr 2025."},{"issue":"1","key":"1812_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S1470-2045(15)00411-8","volume":"17","author":"T Takashima","year":"2016","unstructured":"Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, et al. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2016;17(1):90\u20138.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1812_CR22","doi-asserted-by":"publisher","first-page":"103657","DOI":"10.1016\/j.esmoop.2024.103657","volume":"9","author":"KP Lo","year":"2024","unstructured":"Lo KP, Liposits G, Arora SP, et al. Adequate assessment yields appropriate care-the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO\/SIOG cancer in the elderly working group. ESMO Open. 2024;9(8):103657.","journal-title":"ESMO Open"},{"issue":"5","key":"1812_CR23","first-page":"612","volume":"9","author":"A Sey","year":"2021","unstructured":"Sey A, McMillan SS, Akosile A. Burden of treatment among elderly patients with cancer: A scoping review. Healthc (Basel). 2021;9(5):612.","journal-title":"Healthc (Basel)"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01812-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-025-01812-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01812-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:04:07Z","timestamp":1781633047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-025-01812-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1812"],"URL":"https:\/\/doi.org\/10.1007\/s12282-025-01812-5","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HM reports honoraria from Eli Lilly, Chugai, and Pfizer. SN reports honoraria from AstraZeneca, Daiichi-Sankyo, Eisai, Eli Lilly, MSD, Taiho, Chugai, and Pfizer. MaHa reports honoraria from Eli Lilly and Pfizer. TY reports honoraria from AstraZeneca, Chugai, Eisai, Eli Lilly, MSD, and Pfizer. KW reports honoraria from AstraZeneca, Daiichi-Sankyo, Eisai, Shionogi, Kyowa-Kirin, Nippon-Kayaku, Novartis, Eli Lilly, Taiho, Chugai, and Pfizer. TN reports honoraria from AstraZeneca, Daiichi-Sankyo, Eisai, Novartis, Eli Lilly, Taiho, Chugai, and Pfizer. MY reports honoraria from AstraZeneca, Daiichi-Sankyo, Eisai, Kyowa-Kirin, Nippon-Kayaku, Eli Lilly, Taiho, Chugai, and Pfizer. TS reports honoraria from Chugai, Novartis, MSD, Taiho, Eisai, Maruho, PDRadiopharma, Nippon-Kayaku, Kyowa-Kirin, AstraZeneca, Eli Lilly, Daiichi-Sankyo and Pfizer; and institutional support from Taiho. TI reports honoraria from Chugai, and Pfizer. MF reports honoraria from Chugai, Taiho, Eisai, Nippon-Kayaku, Eli Lilly, and Daiichi-Sankyo. HO is an employee of Pfizer Inc. and stockholder in Pfizer Inc. YM is an employee of Pfizer Inc. and stockholder in Pfizer Inc. NoMa reports honoraria from Chugai, Pfizer, AstraZeneca, Eli Lilly, and Daiichi-Sankyo; and institutional support from Chugai, Eli Lilly, AstraZeneca, Pfizer, Daiichi-Sankyo, MSD, Eisai, Novartis, Sanofi, Kyowa-Kirin, and Nippon-Kayaku. TO, MT, DT, MiHa, HiYo, NaMo, HiYa, CO, MI, and SS have no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study used for this analysis was conducted in accordance with ethical principles of the Declaration of Helsinki, the International Council for Harmonisation (ICH) Harmonised Tripartite Guideline for Good Clinical Practice (GCP), and the Institutional Review Board (IRB) regulations. Clinical study protocols, informed consent forms, and other study-related documents were reviewed and approved by the relevant local or central institutional review board. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}